Researchers at the Gladstone-Institute of Neurological Disease in San Francisco have discovered that the blood-brain barrier actively transports specific proteins from the body into the brain using a molecular postcode system, and that failing supply lines of helpful proteins precede the onset of Alzheimer-like disease in mice.
The blood-brain barrier traditionally earned its reputation as a strict fortress. It shields the central nervous system from circulating toxins and pathogens by keeping most substances out of the cranial vault.
Yet researchers led by Haoyue Zhou at the Gladstone-Institute of Neurological Disease in San Francisco discovered that this interface also operates an active transport system. This network ferries vital proteins from the general circulation directly into the brain.
Which proteins cross the barrier from the body?
To map this physiological transit, the team marked all proteins in the blood of mice and examined brain tissue sections to see which molecules successfully arrived inside the thinking organ. Out of 861 tracked proteins, exactly 92 crossed the blood-brain barrier.
Now online! The blood-brain barrier imports diverse neuroprotective proteins through pathways impaired early in Alzheimer’s disease models dlvr.it/TWHrrY pic.twitter.com/h9PA1fto0w
Many of these travelers originated in distant organs, primarily the liver, adipose tissue, and the gut. Specialized receptors on the barrier cells identify specific plasma proteins and escort them inward, acting as targeted gatekeepers.
As Zhou and her team reported in Cell, these blood proteins function as messengers carrying signals from distant regions.
“We view blood proteins as messengers transmitting signals from distant body regions,” Zhou explained to wissenschaft.de. “The cells of the blood-brain barrier only let those into the brain that the brain really needs.”
How does the molecular postcode system function?
Once inside, the imported proteins are routed to specific cell types to carry out designated tasks. This sorting mechanism operates like a molecular postcode system that guides each protein to its correct destination.
For instance, liver-produced APOA1 is primarily absorbed by astrocytes, which are star-shaped cells in the brain. Once there, APOA1 activates a signaling pathway that maintains healthy connections between neurons.
Because this specific pathway intersects with Alzheimer’s disease development, the researchers examined genetically modified mice bred to model the condition. While scientists already knew the barrier weakens during advanced Alzheimer’s and admits harmful agents, the team uncovered an earlier failure.
“Before the barrier starts letting harmful proteins into the brain, it stops letting the useful ones through,” Zhou told wissenschaft.de. “The brain’s supply line from the body begins to fail.”
This disrupted transport of APOA1 coincided with the breakdown of neuronal connections and behavioral changes in the mice. When investigators stimulated the mouse livers to produce extra APOA1, higher blood levels forced enough of the protein through to reduce Alzheimer-like signs in both brain tissue and animal behavior.
What do these findings mean for future therapies?
These findings suggest that neurodegenerative decline might originate when the body’s vascular supply line to the brain breaks down rather than starting exclusively within cranial tissue.
“The Alzheimer’s disease may not begin exclusively in the brain; it could arise when the brain’s supply line from the body is interrupted,” said Andrew Yang, a co-author from the Gladstone-Institute, as reported by wissenschaft.de. “If that is true, we might be able to combat this disease from outside the brain by restoring what the brain has lost.”
| Metric | Observation |
|---|---|
| Proteins Tracked | 861 |
| Proteins Crossing Barrier | 92 |
| Primary Source Organs | Liver, adipose tissue, gut |
| Key Protein Analyzed | APOA1 |
The mapped catalog of necessary proteins and transport mechanisms also offers blueprints for designing next-generation drug delivery shuttles. Researchers aim to build systems that act from the outside in, carrying effective treatments across the blood-brain barrier.
